<DOC>
	<DOCNO>NCT00723528</DOCNO>
	<brief_summary>The purpose study evaluate safety efficacy ustekinumab ( CNTO 1275 ) compare placebo participant moderate severe plaque type psoriasis .</brief_summary>
	<brief_title>An Efficacy Safety Study Ustekinumab ( CNTO 1275 ) Participants With Plaque Psoriasis</brief_title>
	<detailed_description>This multicenter ( involve 1 study center ) , randomize ( study medication assign chance ) , double-blind ( neither invesitigator participant know identity study medication ) , placebo- control ( 1 study medication inactive ) , parallel-group comparative study ( different group participant receive different treatment time ) . The total duration study 78 week comprise : screening period ( 6 week ) ; efficacy assessment period ( 64 week [ total 7 treatment Weeks 0 , 4 , 12 , 16 , 28 , 40 , 52 ] ) follow-up assessment period ( 8 week ) . The efficacy assessment period include : placebo-controlled treatment period ( Weeks 0-12 ) active drug treatment period ( Weeks 12-64 ) . During placebo-controlled treatment period , participant receive ustekinumab ( 45 mg 90 mg ) subcutaneously ( SC-into muscle ) placebo SC . During active drug treatment period , participant continue treatment 45 mg 90 mg SC assign placebo-controlled treatment period ; however , participant placebo group divide 2 group receive ustekinumab 45 mg ( Placebo A ) 90 mg ( Placebo B ) SC . Efficacy evaluate primarily analysis psoriasis area severity index ( PASI ) score . Participant safety also monitor .</detailed_description>
	<mesh_term>Psoriasis</mesh_term>
	<mesh_term>Ustekinumab</mesh_term>
	<criteria>Participants diagnose psoriasis ( psoriasis vulgaris psoriatic arthritis ) least 6 month registration Participants plaque type psoriasis cover least 10 percent total body surface area time inform consent registration Participants PASI score great equal 12 time inform consent registration Female participant childbearing potential male , whose partner pregnant , must agree he/she continuously take appropriate contraceptive measure 1 year day inform consent termination final investigational treatment ; case childbearing potential female , pregnancy test screening must negative Participants must agree receive Bacillus CalmetteGu√©rin ( BCG ) vaccination live vaccine inoculation 1 year final treatment investigational product Participants guttate psoriasis , erythrodermic psoriasis , pustular psoriasis Participants medical history tuberculosis infection suspect tuberculosis infection Participants present past history chronic recurrent infection ( e.g. , chronic recurrent urinary tract infection respiratory infection ) Participants current serious infection ( e.g. , sepsis , hepatitis , pneumonia , pyelonephritis ) experience serious infection within 2 month period registration include participant receive intravenous administration antibiotic antiviral agent within 2 month period registration Participants current past history malignant tumor ( except basal cell carcinoma , intraepidermal squamous cell carcinoma skin uterine cervical squamous cell carcinoma , whose treatment complete sign suggest recurrence observe , squamous cell carcinoma skin whose treatment complete sign suggest recurrence observe past 5 year )</criteria>
	<gender>All</gender>
	<minimum_age>20 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>April 2014</verification_date>
	<keyword>Psoriasis</keyword>
	<keyword>Ustekinumab</keyword>
	<keyword>CNTO 1275</keyword>
</DOC>